Research programme: glycan based therapeutics - CHO Pharma

Drug Profile

Research programme: glycan based therapeutics - CHO Pharma

Alternative Names: CHO S05; CHO V07; Dual-effect anti-flu drugs

Latest Information Update: 20 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Academia Sinica
  • Developer CHO Pharma
  • Class Antivirals; Vaccines
  • Mechanism of Action Cytokine inhibitors; Influenza A virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Influenza virus infections

Most Recent Events

  • 20 Jul 2017 CHO Pharma has patent protection for glycan based vaccine and drugs in USA, Europe, South Korea, Japan, Canada, China and Australia (CHO Pharma website, July 2017)
  • 20 Jul 2017 CHO Pharma has patents pending for glycan based vaccine and drugs in Taiwan (CHO Pharma website, July 2017)
  • 20 Jul 2017 Preclinical trials in Influenza virus infections in Taiwan (PO) (CHO Pharma pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top